HealthDay on MSN13h
Cases of COVID-19 in Those With Epilepsy Low Early in the Pandemic
On a global scale, people with epilepsy reported low rates of COVID-19 early in the pandemic, according to a study published ...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal ...
COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
High-grade masks evidence weak, Covid inquiry told
There is only “weak evidence” that high-grade face masks better protected health workers than surgical ones in the pandemic, the Covid inquiry has been told.
SBS1d
A new COVID vaccine is coming, but there's another one Australians won't be able to get
1 lineage in the make-up of future COVID-19 vaccines in April. The adapted Pfizer and Moderna JN.1 vaccines were approved by the United Kingdom's regular in July and, later, this month.
London's ExCel Centre wins insurance appeal over COVID-19 losses
The owners of London's ExCel conference centre on Friday won an appeal brought by insurers, including Allianz , over pandemic ...
BioNTech SE: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...